(-)-demecolcine increases expression ISO RGD:732028 6480464 Demecolcine results in increased expression of NR4A2 mRNA CTD PMID:23649840 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:732028 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A2 mRNA CTD PMID:22079256 1,2,4-trimethylbenzene increases expression ISO RGD:3202 6480464 pseudocumene results in increased expression of NR4A2 protein CTD PMID:17337753 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine multiple interactions EXP 6480464 1 more ... CTD PMID:25406165 17beta-estradiol increases expression ISO RGD:732028 6480464 Estradiol results in increased expression of NR4A2 mRNA CTD PMID:19153601 17beta-estradiol decreases expression ISO RGD:732028 6480464 Estradiol results in decreased expression of NR4A2 mRNA CTD PMID:21185374 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions EXP 6480464 [2 more ... CTD PMID:25510870 2,2',5,5'-tetrachlorobiphenyl multiple interactions EXP 6480464 [2 more ... CTD PMID:25510870 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of NR4A2 mRNA CTD PMID:21570461 , PMID:24058054 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:732028 6480464 Tetrachlorodibenzodioxin results in decreased expression of NR4A2 mRNA CTD PMID:29704546 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:732028 6480464 [Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in increased expression of NR4A2 mRNA CTD PMID:29704546 2-hydroxypropanoic acid increases expression ISO RGD:732028 6480464 Lactic Acid results in increased expression of NR4A2 mRNA CTD PMID:30851411 3,4-methylenedioxymethamphetamine decreases expression EXP 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of NR4A2 mRNA CTD PMID:20188158 3,7-dihydropurine-6-thione increases expression ISO RGD:3202 6480464 Mercaptopurine results in increased expression of NR4A2 mRNA CTD PMID:27435855 3,7-dihydropurine-6-thione multiple interactions ISO RGD:3202 6480464 [GW 1929 co-treated with Mercaptopurine] results in increased expression of NR4A2 mRNA more ... CTD PMID:27435855 4,4'-diaminodiphenylmethane increases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in increased expression of NR4A2 mRNA CTD PMID:18648102 6-propyl-2-thiouracil increases expression ISO RGD:3202 6480464 Propylthiouracil results in increased expression of NR4A2 mRNA CTD PMID:22504374 6-propyl-2-thiouracil decreases expression ISO RGD:3202 6480464 Propylthiouracil results in decreased expression of NR4A2 mRNA CTD PMID:25825206 8-bromo-3',5'-cyclic AMP increases expression ISO RGD:732028 6480464 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A2 mRNA CTD PMID:22079614 acetaldehyde increases expression ISO RGD:732028 6480464 Acetaldehyde results in increased expression of NR4A2 mRNA CTD PMID:23416264 acrylamide decreases expression ISO RGD:3202 6480464 Acrylamide results in decreased expression of NR4A2 mRNA CTD PMID:22197712 acrylamide affects expression ISO RGD:3202 6480464 Acrylamide affects the expression of NR4A2 mRNA CTD PMID:28959563 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of NR4A2 mRNA CTD PMID:19770486 aflatoxin B1 affects expression ISO RGD:732028 6480464 Aflatoxin B1 affects the expression of NR4A2 protein CTD PMID:20106945 all-trans-retinoic acid multiple interactions ISO RGD:732028 6480464 [Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NR4A2 mRNA CTD PMID:17085092 amiodarone increases expression ISO RGD:732028 6480464 Amiodarone results in increased expression of NR4A2 mRNA CTD PMID:19774075 ammonium chloride affects expression ISO RGD:3202 6480464 Ammonium Chloride affects the expression of NR4A2 mRNA CTD PMID:16483693 arachidonic acid decreases expression ISO RGD:732028 6480464 Arachidonic Acid results in decreased expression of NR4A2 mRNA CTD PMID:16704987 arsane decreases expression ISO RGD:732028 6480464 Arsenic results in decreased expression of NR4A2 mRNA CTD PMID:16835338 arsane decreases expression EXP 6480464 Arsenic results in decreased expression of NR4A2 mRNA CTD PMID:19654921 arsenic atom decreases expression ISO RGD:732028 6480464 Arsenic results in decreased expression of NR4A2 mRNA CTD PMID:16835338 arsenic atom decreases expression EXP 6480464 Arsenic results in decreased expression of NR4A2 mRNA CTD PMID:19654921 arsenous acid decreases expression ISO RGD:732028 6480464 Arsenic Trioxide results in decreased expression of NR4A2 mRNA CTD PMID:26705709 atrazine decreases expression ISO RGD:3202 6480464 Atrazine results in decreased expression of NR4A2 mRNA, Atrazine results in decreased expression of NR4A2 protein CTD PMID:24552878 more ... benzalkonium chloride increases expression ISO RGD:732028 6480464 Benzalkonium Compounds results in increased expression of NR4A2 mRNA CTD PMID:25377654 benzene increases expression ISO RGD:732028 6480464 Benzene results in increased expression of NR4A2 mRNA CTD PMID:19162166 benzo[a]pyrene increases expression EXP 6480464 Benzo(a)pyrene results in increased expression of NR4A2 mRNA CTD PMID:21569818 benzo[a]pyrene diol epoxide I increases expression ISO RGD:732028 6480464 7 more ... CTD PMID:20382639 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:732028 6480464 7 more ... CTD PMID:20018196 bisphenol A affects expression ISO RGD:3202 6480464 bisphenol A affects the expression of NR4A2 mRNA CTD PMID:25181051 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of NR4A2 mRNA CTD PMID:30951980 bisphenol A increases methylation ISO RGD:3202 6480464 bisphenol A results in increased methylation of NR4A2 gene CTD PMID:28505145 bisphenol A affects methylation EXP 6480464 bisphenol A affects the methylation of NR4A2 promoter CTD PMID:27334623 bisphenol F increases expression EXP 6480464 bisphenol F results in increased expression of NR4A2 mRNA CTD PMID:30951980 buta-1,3-diene decreases expression EXP 6480464 1, 3-butadiene results in decreased expression of NR4A2 mRNA CTD PMID:29038090 butanal increases expression ISO RGD:732028 6480464 butyraldehyde results in increased expression of NR4A2 mRNA CTD PMID:26079696 cadmium atom increases expression ISO RGD:732028 6480464 Cadmium results in increased expression of NR4A2 mRNA CTD PMID:21694771 cadmium dichloride increases expression ISO RGD:732028 6480464 Cadmium Chloride results in increased expression of NR4A2 mRNA CTD PMID:26472689 Calcimycin increases expression EXP 6480464 Calcimycin results in increased expression of NR4A2 mRNA CTD PMID:25451590 Calcimycin multiple interactions EXP 6480464 shikonin inhibits the reaction [Calcimycin results in increased expression of NR4A2 mRNA] CTD PMID:25451590 carbon nanotube decreases expression EXP 6480464 Nanotubes, Carbon analog results in decreased expression of NR4A2 mRNA, Nanotubes, Carbon results in decreased expression of NR4A2 mRNA CTD PMID:25554681 carmustine affects expression ISO RGD:3202 6480464 Carmustine affects the expression of NR4A2 mRNA CTD PMID:19174181 Carnosol increases expression EXP 6480464 carnosol results in increased expression of NR4A2 protein CTD PMID:17047462 chlorpyrifos decreases expression EXP 6480464 Chlorpyrifos results in decreased expression of NR4A2 mRNA CTD PMID:29156651 choline multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of NR4A2 gene CTD PMID:20938992 clozapine increases expression EXP 6480464 Clozapine results in increased expression of NR4A2 mRNA CTD PMID:17266109 cobalt dichloride increases expression ISO RGD:732028 6480464 cobaltous chloride results in increased expression of NR4A2 mRNA CTD PMID:19376846 cocaine decreases expression ISO RGD:732028 6480464 Cocaine results in decreased expression of NR4A2 protein CTD PMID:15094491 Colforsin dapropate hydrochloride increases expression ISO RGD:732028 6480464 Colforsin results in increased expression of NR4A2 protein CTD PMID:19732956 Colforsin dapropate hydrochloride multiple interactions ISO RGD:732028 6480464 NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] CTD PMID:19822197 copper(II) sulfate increases expression ISO RGD:732028 6480464 Copper Sulfate results in increased expression of NR4A2 mRNA CTD PMID:19549813 coumestrol multiple interactions ISO RGD:732028 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NR4A2 mRNA CTD PMID:19167446 crocidolite asbestos affects expression ISO RGD:732028 6480464 Asbestos, Crocidolite affects the expression of NR4A2 mRNA CTD PMID:25757056 crocidolite asbestos increases expression ISO RGD:732028 6480464 Asbestos, Crocidolite results in increased expression of NR4A2 mRNA CTD PMID:18687144 , PMID:24160326 curcumin decreases expression ISO RGD:732028 6480464 Curcumin results in decreased expression of NR4A2 mRNA CTD PMID:17999991 cyclosporin A multiple interactions EXP 6480464 Cyclosporine inhibits the reaction [Antigen-Antibody Complex results in increased expression of NR4A2 mRNA] CTD PMID:25451590 DDE increases activity ISO RGD:732028 6480464 Dichlorodiphenyl Dichloroethylene results in increased activity of NR4A2 protein CTD PMID:27589886 decabromodiphenyl ether decreases expression ISO RGD:3202 6480464 decabromobiphenyl ether results in decreased expression of NR4A2 mRNA CTD PMID:23914054 diarsenic trioxide decreases expression ISO RGD:732028 6480464 Arsenic Trioxide results in decreased expression of NR4A2 mRNA CTD PMID:26705709 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of NR4A2 mRNA CTD PMID:21266533 dieldrin affects methylation EXP 6480464 Dieldrin affects the methylation of NR4A2 gene CTD PMID:30859219 diheptyl phthalate decreases expression ISO RGD:3202 6480464 diheptyl phthalate results in decreased expression of NR4A2 mRNA CTD PMID:22112501 disodium selenite increases expression ISO RGD:732028 6480464 Sodium Selenite results in increased expression of NR4A2 mRNA CTD PMID:18175754 dorsomorphin multiple interactions ISO RGD:732028 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR4A2 mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:732028 6480464 Doxorubicin results in decreased expression of NR4A2 mRNA CTD PMID:29803840 Enterolactone multiple interactions ISO RGD:732028 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NR4A2 mRNA CTD PMID:19167446 flavonoids decreases expression ISO RGD:3202 6480464 Flavonoids results in decreased expression of NR4A2 mRNA CTD PMID:18035473 fluoranthene multiple interactions EXP 6480464 [1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A2 mRNA CTD PMID:28329830 fluoxetine decreases expression EXP 6480464 Fluoxetine results in decreased expression of NR4A2 mRNA CTD PMID:20857517 flutamide increases expression ISO RGD:3202 6480464 Flutamide results in increased expression of NR4A2 mRNA CTD PMID:24793618 folic acid multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of NR4A2 gene CTD PMID:20938992 formaldehyde increases expression ISO RGD:732028 6480464 Formaldehyde results in increased expression of NR4A2 mRNA CTD PMID:17938736 , PMID:20655997 gamma-hexachlorocyclohexane increases expression ISO RGD:3202 6480464 Hexachlorocyclohexane results in increased expression of NR4A2 mRNA CTD PMID:8737662 geraniol increases expression ISO RGD:732028 6480464 geraniol results in increased expression of NR4A2 mRNA CTD PMID:27683099 glutathione multiple interactions ISO RGD:3202 6480464 Glutathione inhibits the reaction [Permethrin results in increased expression of NR4A2 mRNA] CTD PMID:28943456 glycidol decreases expression ISO RGD:3202 6480464 glycidol results in decreased expression of NR4A2 mRNA CTD PMID:24915197 glycidol increases expression ISO RGD:3202 6480464 glycidol results in increased expression of NR4A2 mRNA CTD PMID:24395379 GW 1929 affects localization ISO RGD:3202 6480464 GW 1929 affects the localization of NR4A2 protein CTD PMID:27435855 GW 1929 multiple interactions ISO RGD:3202 6480464 [GW 1929 co-treated with Mercaptopurine] results in increased expression of NR4A2 mRNA, [GW 1929 co-treated with Mercaptopurine] results in increased expression of NR4A2 protein CTD PMID:27435855 heroin decreases expression ISO RGD:3202 6480464 Heroin results in decreased expression of NR4A2 mRNA CTD PMID:25643298 hydroquinone decreases expression ISO RGD:732028 6480464 hydroquinone results in decreased expression of NR4A2 mRNA CTD PMID:31256213 indometacin decreases expression ISO RGD:732028 6480464 Indomethacin results in decreased expression of NR4A2 mRNA CTD PMID:24737281 kainic acid increases expression ISO RGD:3202 6480464 Kainic Acid results in increased expression of NR4A2 mRNA CTD PMID:19700661 kainic acid increases expression EXP 6480464 Kainic Acid results in increased expression of NR4A2 protein CTD PMID:24813937 ketamine decreases expression ISO RGD:3202 6480464 Ketamine results in decreased expression of NR4A2 mRNA CTD PMID:20080153 L-methionine multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of NR4A2 gene CTD PMID:20938992 leptomycin B multiple interactions EXP 6480464 leptomycin B inhibits the reaction [sodium arsenite affects the localization of NR4A2 protein] CTD PMID:23283970 lithium atom increases expression ISO RGD:732028 6480464 Lithium results in increased expression of NR4A2 mRNA CTD PMID:21092101 lithium chloride multiple interactions ISO RGD:3202 6480464 CTNNB1 protein affects the reaction [Lithium Chloride results in increased expression of NR4A2 mRNA] more ... CTD PMID:27045591 lithium chloride increases expression ISO RGD:3202 6480464 Lithium Chloride results in increased expression of NR4A2 mRNA, Lithium Chloride results in increased expression of NR4A2 protein CTD PMID:27045591 lithium hydride increases expression ISO RGD:732028 6480464 Lithium results in increased expression of NR4A2 mRNA CTD PMID:21092101 lucanthone increases expression ISO RGD:732028 6480464 Lucanthone results in increased expression of NR4A2 mRNA CTD PMID:21148553 maneb multiple interactions ISO RGD:3202 6480464 [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA, [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein CTD PMID:29152652 medroxyprogesterone acetate decreases expression ISO RGD:732028 6480464 Medroxyprogesterone Acetate results in decreased expression of NR4A2 mRNA CTD PMID:20843944 mercaptopurine multiple interactions ISO RGD:3202 6480464 [GW 1929 co-treated with Mercaptopurine] results in increased expression of NR4A2 mRNA more ... CTD PMID:27435855 mercaptopurine increases expression ISO RGD:3202 6480464 Mercaptopurine results in increased expression of NR4A2 mRNA CTD PMID:27435855 methamphetamine multiple interactions EXP 6480464 NR4A2 protein affects the reaction [Methamphetamine results in decreased expression of SLC6A3 protein], NR4A2 protein affects the reaction [Methamphetamine results in decreased expression of TH protein] CTD PMID:21151937 methamphetamine increases expression ISO RGD:3202 6480464 Methamphetamine results in increased expression of NR4A2 mRNA CTD PMID:19564919 methamphetamine multiple interactions ISO RGD:3202 6480464 [Methamphetamine co-treated with SCH 23390] results in increased expression of NR4A2 mRNA CTD PMID:19564919 methamphetamine affects response to substance EXP 6480464 NR4A2 protein affects the susceptibility to Methamphetamine CTD PMID:21151937 methimazole increases expression ISO RGD:3202 6480464 Methimazole results in increased expression of NR4A2 mRNA CTD PMID:22504374 methotrexate decreases expression ISO RGD:732028 6480464 Methotrexate results in decreased expression of NR4A2 CTD PMID:19732956 methylmercury chloride affects expression EXP 6480464 methylmercuric chloride affects the expression of NR4A2 mRNA CTD PMID:21613230 methylmercury chloride increases expression ISO RGD:732028 6480464 methylmercuric chloride results in increased expression of NR4A2 mRNA CTD PMID:28001369 mitoxantrone affects response to substance ISO RGD:732028 6480464 NR4A2 protein affects the susceptibility to Mitoxantrone CTD PMID:16217747 mono(2-ethylhexyl) phthalate increases expression ISO RGD:732028 6480464 mono-(2-ethylhexyl)phthalate results in increased expression of NR4A2 mRNA CTD PMID:19822197 morphine decreases expression ISO RGD:3202 6480464 Morphine results in decreased expression of NR4A2 mRNA CTD PMID:25643298 morphine multiple interactions ISO RGD:3202 6480464 Morphine inhibits the reaction [CREB1 protein modified form binds to NR4A2 promoter], Morphine inhibits the reaction [NR4A2 protein binds to BDNF promoter] CTD PMID:25643298 morphine affects response to substance EXP 6480464 NR4A2 protein affects the susceptibility to Morphine CTD PMID:25643298 morphine multiple interactions EXP 6480464 BDNF protein inhibits the reaction [NR4A2 protein affects the susceptibility to Morphine] CTD PMID:25643298 N(6)-butyryl-cAMP multiple interactions ISO RGD:3202 6480464 CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA] CTD PMID:25381014 N(6)-butyryl-cAMP increases expression ISO RGD:3202 6480464 monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA CTD PMID:25381014 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide multiple interactions ISO RGD:732028 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA], N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein] CTD PMID:22188298 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of NR4A2 mRNA CTD PMID:26558463 naphthalenes increases expression ISO RGD:3202 6480464 Naphthalenes results in increased expression of NR4A2 protein CTD PMID:17337753 nickel atom increases expression ISO RGD:732028 6480464 Nickel results in increased expression of NR4A2 mRNA CTD PMID:23195993 nickel sulfate increases expression ISO RGD:732028 6480464 nickel sulfate results in increased expression of NR4A2 mRNA CTD PMID:16780908 paraquat multiple interactions ISO RGD:3202 6480464 [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA, [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein CTD PMID:29152652 paricalcitol multiple interactions ISO RGD:732028 6480464 [Phosphorus co-treated with paricalcitol] affects the expression of NR4A2 mRNA CTD PMID:17715259 pentetrazol increases expression EXP 6480464 Pentylenetetrazole results in increased expression of NR4A2 mRNA CTD PMID:8164692 perfluorooctane-1-sulfonic acid affects expression EXP 6480464 perfluorooctane sulfonic acid affects the expression of NR4A2 mRNA CTD PMID:19429403 perfluorooctanoic acid affects expression EXP 6480464 perfluorooctanoic acid affects the expression of NR4A2 mRNA CTD PMID:19429403 permethrin decreases expression ISO RGD:3202 6480464 Permethrin results in decreased expression of NR4A2 more ... CTD PMID:22056222 more ... permethrin multiple interactions ISO RGD:3202 6480464 Glutathione inhibits the reaction [Permethrin results in increased expression of NR4A2 mRNA], Tocotrienols inhibits the reaction [Permethrin results in increased expression of NR4A2 mRNA] CTD PMID:28943456 permethrin affects expression ISO RGD:3202 6480464 Permethrin affects the expression of NR4A2 mRNA CTD PMID:23566817 permethrin increases expression ISO RGD:3202 6480464 Permethrin results in increased expression of NR4A2 mRNA, Permethrin results in increased expression of NR4A2 protein CTD PMID:23566817 more ... phencyclidine increases expression EXP 6480464 Phencyclidine results in increased expression of NR4A2 mRNA CTD PMID:17266109 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:732028 6480464 [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of NR4A2 mRNA CTD PMID:16979875 phosphorus atom multiple interactions ISO RGD:732028 6480464 [Phosphorus co-treated with paricalcitol] affects the expression of NR4A2 mRNA CTD PMID:17715259 phosphorus(.) multiple interactions ISO RGD:732028 6480464 [Phosphorus co-treated with paricalcitol] affects the expression of NR4A2 mRNA CTD PMID:17715259 pirimiphos-methyl increases activity ISO RGD:732028 6480464 pirimiphos methyl results in increased activity of NR4A2 protein CTD PMID:20143881 pirinixic acid multiple interactions ISO RGD:732028 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of NR4A2 mRNA CTD PMID:19710929 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of NR4A2 mRNA CTD PMID:18301758 , PMID:20813756 potassium chloride increases expression ISO RGD:3202 6480464 Potassium Chloride results in increased expression of NR4A2 mRNA CTD PMID:8737662 potassium chromate multiple interactions ISO RGD:732028 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A2 mRNA CTD PMID:22079256 potassium chromate increases expression ISO RGD:732028 6480464 potassium chromate(VI) results in increased expression of NR4A2 mRNA CTD PMID:22079256 proanthocyanidin multiple interactions ISO RGD:732028 6480464 Proanthocyanidins inhibits the reaction [quinocetone metabolite results in decreased expression of NR4A2 mRNA] CTD PMID:26802905 probenecid multiple interactions EXP 6480464 1 more ... CTD PMID:25406165 propanal decreases expression ISO RGD:732028 6480464 propionaldehyde results in decreased expression of NR4A2 mRNA CTD PMID:26079696 prostaglandin E2 increases expression EXP 6480464 Dinoprostone results in increased expression of NR4A2 CTD PMID:16293616 prostaglandin E2 multiple interactions ISO RGD:732028 6480464 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein] more ... CTD PMID:22188298 purine-6-thiol multiple interactions ISO RGD:3202 6480464 [GW 1929 co-treated with Mercaptopurine] results in increased expression of NR4A2 mRNA more ... CTD PMID:27435855 purine-6-thiol increases expression ISO RGD:3202 6480464 Mercaptopurine results in increased expression of NR4A2 mRNA CTD PMID:27435855 rac-lactic acid increases expression ISO RGD:732028 6480464 Lactic Acid results in increased expression of NR4A2 mRNA CTD PMID:30851411 reactive oxygen species multiple interactions ISO RGD:732028 6480464 [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of NR4A2 mRNA CTD PMID:27634759 rotenone decreases expression ISO RGD:3202 6480464 Rotenone results in decreased expression of NR4A2 mRNA, Rotenone results in decreased expression of NR4A2 protein CTD PMID:19013527 more ... rotenone affects expression ISO RGD:732028 6480464 Rotenone affects the expression of NR4A2 mRNA CTD PMID:29428530 rotenone multiple interactions ISO RGD:3202 6480464 Lithium Chloride inhibits the reaction [Rotenone results in decreased expression of NR4A2 protein] CTD PMID:27045591 SB 431542 multiple interactions ISO RGD:732028 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR4A2 mRNA CTD PMID:27188386 SCH 23390 multiple interactions ISO RGD:3202 6480464 [Methamphetamine co-treated with SCH 23390] results in increased expression of NR4A2 mRNA CTD PMID:19564919 SCH 23390 increases expression ISO RGD:3202 6480464 SCH 23390 results in increased expression of NR4A2 mRNA CTD PMID:19564919 serpentine asbestos increases expression ISO RGD:732028 6480464 Asbestos, Serpentine results in increased expression of NR4A2 mRNA CTD PMID:24160326 Shikonin multiple interactions EXP 6480464 shikonin inhibits the reaction [Antigen-Antibody Complex results in increased expression of NR4A2 mRNA], shikonin inhibits the reaction [Calcimycin results in increased expression of NR4A2 mRNA] CTD PMID:25451590 silicon dioxide decreases expression ISO RGD:732028 6480464 Silicon Dioxide analog results in decreased expression of NR4A2 mRNA CTD PMID:25895662 silicon dioxide decreases expression EXP 6480464 Silicon Dioxide results in decreased expression of NR4A2 mRNA CTD PMID:29203145 silicon dioxide increases expression ISO RGD:732028 6480464 Silicon Dioxide analog results in increased expression of NR4A2 mRNA CTD PMID:23806026 silicon dioxide increases expression EXP 6480464 Silicon Dioxide results in increased expression of NR4A2 mRNA CTD PMID:19073995 silver atom affects expression EXP 6480464 Silver affects the expression of NR4A2 mRNA CTD PMID:27131904 silver(0) affects expression EXP 6480464 Silver affects the expression of NR4A2 mRNA CTD PMID:27131904 simazine affects expression EXP 6480464 Simazine affects the expression of NR4A2 mRNA CTD PMID:27513680 simazine decreases expression ISO RGD:3202 6480464 Simazine results in decreased expression of NR4A2 mRNA, Simazine results in decreased expression of NR4A2 protein CTD PMID:29115391 sodium arsenite multiple interactions EXP 6480464 [sodium arsenite affects the localization of NR4A2 protein] inhibits the reaction [NR4A2 protein results in increased expression of DDC mRNA] more ... CTD PMID:23283970 sodium arsenite decreases expression ISO RGD:732028 6480464 sodium arsenite results in decreased expression of NR4A2 mRNA CTD PMID:29301061 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of NR4A2 mRNA CTD PMID:18812580 sodium arsenite affects localization EXP 6480464 sodium arsenite affects the localization of NR4A2 protein CTD PMID:23283970 sodium dichromate increases expression EXP 6480464 sodium bichromate results in increased expression of NR4A2 mRNA CTD PMID:27859739 sodium dodecyl sulfate increases expression ISO RGD:732028 6480464 Sodium Dodecyl Sulfate results in increased expression of NR4A2 mRNA CTD PMID:25377654 sodium fluoride decreases expression EXP 6480464 Sodium Fluoride results in decreased expression of NR4A2 mRNA CTD PMID:27862939 Soman increases expression ISO RGD:3202 6480464 Soman results in increased expression of NR4A2 mRNA CTD PMID:19281266 Soman decreases expression ISO RGD:3202 6480464 Soman results in decreased expression of NR4A2 mRNA CTD PMID:19281266 styrene decreases expression EXP 6480464 Styrene results in decreased expression of NR4A2 mRNA CTD PMID:28951217 tamoxifen increases expression EXP 6480464 Tamoxifen results in increased expression of NR4A2 mRNA CTD PMID:25123088 tetradecane increases expression ISO RGD:3202 6480464 n-tetradecane results in increased expression of NR4A2 protein CTD PMID:17337753 thalidomide increases expression ISO RGD:732028 6480464 Thalidomide analog results in increased expression of NR4A2 mRNA CTD PMID:20525221 thapsigargin increases expression ISO RGD:732028 6480464 Thapsigargin results in increased expression of NR4A2 mRNA CTD PMID:21694771 , PMID:29453283 thimerosal increases expression ISO RGD:732028 6480464 Thimerosal results in increased expression of NR4A2 mRNA CTD PMID:16870260 titanium dioxide increases expression EXP 6480464 titanium dioxide results in increased expression of NR4A2 mRNA CTD PMID:23557971 titanium dioxide decreases expression EXP 6480464 titanium dioxide results in decreased expression of NR4A2 mRNA CTD PMID:29264374 topiramate decreases expression ISO RGD:3202 6480464 topiramate results in decreased expression of NR4A2 mRNA CTD PMID:16979414 torcetrapib increases expression ISO RGD:732028 6480464 torcetrapib results in increased expression of NR4A2 mRNA CTD PMID:19164467 more ... triacsin C decreases expression ISO RGD:732028 6480464 triacsin C results in decreased expression of NR4A2 mRNA CTD PMID:16704987 trichostatin A increases expression ISO RGD:732028 6480464 trichostatin A results in increased expression of NR4A2 mRNA CTD PMID:24935251 troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of NR4A2 mRNA CTD PMID:28973697 undecane increases expression ISO RGD:3202 6480464 undecane results in increased expression of NR4A2 protein CTD PMID:17337753 urethane decreases expression ISO RGD:732028 6480464 Urethane results in decreased expression of NR4A2 mRNA CTD PMID:28818685 valproic acid increases expression ISO RGD:3202 6480464 Valproic Acid results in increased expression of NR4A2 mRNA CTD PMID:28743636 valproic acid multiple interactions ISO RGD:3202 6480464 Valproic Acid promotes the reaction [NR4A2 protein binds to SLC6A3 promoter] CTD PMID:28743636 valproic acid multiple interactions ISO RGD:732028 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR4A2 mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:732028 6480464 Valproic Acid results in decreased expression of NR4A2 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:732028 6480464 Valproic Acid results in increased expression of NR4A2 mRNA CTD PMID:23179753 more ... vinclozolin affects expression ISO RGD:3202 6480464 vinclozolin affects the expression of NR4A2 mRNA CTD PMID:19015723 vitamin D decreases expression ISO RGD:3202 6480464 Vitamin D deficiency results in decreased expression of NR4A2 mRNA, Vitamin D deficiency results in decreased expression of NR4A2 protein CTD PMID:28365874 zinc atom multiple interactions ISO RGD:732028 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of NR4A2 mRNA, [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of NR4A2 mRNA CTD PMID:16979875 , PMID:18593933 zinc(0) multiple interactions ISO RGD:732028 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of NR4A2 mRNA, [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of NR4A2 mRNA CTD PMID:16979875 , PMID:18593933
Biological Process adult locomotory behavior IMP MGI:MGI:2429971 2290270 (MGI:MGI:3529728, PMID:12385813) MGI MGI:MGI:3529728 , PMID:12385813 cellular response to corticotropin-releasing hormone stimulus IDA 2290270 (MGI:MGI:5645213, PMID:10523643) UniProtKB MGI:MGI:5645213 , PMID:10523643 cellular response to corticotropin-releasing hormone stimulus IBA MGI:MGI:1352454 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 cellular response to extracellular stimulus ISO UniProtKB:P43354 2290270 (MGI:MGI:69943, PMID:7877627) MGI MGI:MGI:69943 , PMID:7877627 cellular response to extracellular stimulus IDA 2290270 (MGI:MGI:84485, PMID:8961274) MGI MGI:MGI:84485 , PMID:8961274 cellular response to oxidative stress IMP 2290270 (MGI:MGI:4462723, PMID:20566846) MGI MGI:MGI:4462723 , PMID:20566846 central nervous system neuron differentiation IMP MGI:MGI:2429971 2290270 (MGI:MGI:1928583, PMID:11113533) MGI MGI:MGI:1928583 , PMID:11113533 central nervous system neuron differentiation IBA MGI:MGI:1352456 , PANTHER:PTN001182600 2290270 (PMID:21873635) GO_Central PMID:21873635 central nervous system projection neuron axonogenesis IMP MGI:MGI:2157566 2290270 (MGI:MGI:1350702, PMID:10585298) MGI MGI:MGI:1350702 , PMID:10585298 dopamine biosynthetic process IMP MGI:MGI:2429971 2290270 (MGI:MGI:1203924 more ... MGI MGI:MGI:1203924 more ... dopamine metabolic process IMP MGI:MGI:2429971 2290270 (MGI:MGI:3529728, PMID:12385813) MGI MGI:MGI:3529728 , PMID:12385813 dopaminergic neuron differentiation TAS 2290270 (MGI:MGI:5700306, PMID:16243425) ParkinsonsUK-UCL MGI:MGI:5700306 , PMID:16243425 dopaminergic neuron differentiation IBA MGI:MGI:1352456 , PANTHER:PTN001182600 2290270 (PMID:21873635) GO_Central PMID:21873635 dopaminergic neuron differentiation IDA 2290270 (MGI:MGI:3830409, PMID:19144721) UniProtKB MGI:MGI:3830409 , PMID:19144721 fat cell differentiation IDA 2290270 (MGI:MGI:5645207, PMID:18945812) UniProtKB MGI:MGI:5645207 , PMID:18945812 gene expression IMP MGI:MGI:2429971 2290270 (MGI:MGI:1343916, PMID:10465447) MGI MGI:MGI:1343916 , PMID:10465447 general adaptation syndrome IMP MGI:MGI:2429971 2290270 (MGI:MGI:3529728, PMID:12385813) MGI MGI:MGI:3529728 , PMID:12385813 habenula development IMP 2290270 (MGI:MGI:4398759, PMID:19906978) MGI MGI:MGI:4398759 , PMID:19906978 negative regulation of apoptotic signaling pathway ISO UniProtKB:P43354 2290270 MGI GO_REF:0000096, MGI:MGI:4834177 negative regulation of neuron apoptotic process IMP MGI:MGI:2157566 2290270 (MGI:MGI:1350702, PMID:10585298) MGI MGI:MGI:1350702 , PMID:10585298 negative regulation of neuron apoptotic process IMP 2290270 (MGI:MGI:4462723, PMID:20566846) MGI MGI:MGI:4462723 , PMID:20566846 negative regulation of transcription by RNA polymerase II ISO UniProtKB:P43354 2290270 MGI GO_REF:0000096, MGI:MGI:4834177 nervous system development IMP MGI:MGI:2157566 2290270 (MGI:MGI:2156967 more ... MGI MGI:MGI:2156967 more ... neuron differentiation IMP MGI:MGI:3043985 2290270 (MGI:MGI:1202150 more ... MGI MGI:MGI:1202150 more ... neuron maturation IMP MGI:MGI:2157566 2290270 (MGI:MGI:1350702, PMID:10585298) MGI MGI:MGI:1350702 , PMID:10585298 neuron migration IMP MGI:MGI:2157566 2290270 (MGI:MGI:1350702, PMID:10585298) MGI MGI:MGI:1350702 , PMID:10585298 positive regulation of catalytic activity IMP MGI:MGI:2429971 2290270 (MGI:MGI:3761857, PMID:11517332) MGI MGI:MGI:3761857 , PMID:11517332 positive regulation of transcription by RNA polymerase II IMP MGI:MGI:2429971 2290270 (MGI:MGI:3767764, PMID:16782508) MGI MGI:MGI:3767764 , PMID:16782508 positive regulation of transcription by RNA polymerase II IDA 2290270 (MGI:MGI:3029599 more ... NTNU_SB MGI:MGI:3029599 more ... positive regulation of transcription by RNA polymerase II ISO RGD:3202 2290270 RGD GO_REF:0000096, MGI:MGI:4417868 positive regulation of transcription by RNA polymerase II IGI MGI:MGI:1352460 2290270 (MGI:MGI:3047463, PMID:15155786) MGI MGI:MGI:3047463 , PMID:15155786 positive regulation of transcription, DNA-templated IDA 2290270 (MGI:MGI:84485, PMID:8961274) MGI MGI:MGI:84485 , PMID:8961274 post-embryonic development IMP MGI:MGI:2429971 2290270 (MGI:MGI:1203924, PMID:9608532) MGI MGI:MGI:1203924 , PMID:9608532 regulation of dopamine metabolic process IDA 2290270 (MGI:MGI:2671567, PMID:12915123) MGI MGI:MGI:2671567 , PMID:12915123 regulation of gene expression IMP 2290270 (MGI:MGI:3850580, PMID:19515692) MGI MGI:MGI:3850580 , PMID:19515692 regulation of respiratory gaseous exchange IMP MGI:MGI:2157566 2290270 (MGI:MGI:3614580, PMID:14742729) MGI MGI:MGI:3614580 , PMID:14742729 regulation of transcription, DNA-templated IMP MGI:MGI:2429971 2290270 (MGI:MGI:4398759, PMID:19906978) MGI MGI:MGI:4398759 , PMID:19906978 response to amphetamine IMP MGI:MGI:2429971 2290270 (MGI:MGI:3529728, PMID:12385813) MGI MGI:MGI:3529728 , PMID:12385813 response to hypoxia IMP MGI:MGI:2157566 2290270 (MGI:MGI:3614580, PMID:14742729) MGI MGI:MGI:3614580 , PMID:14742729 response to inorganic substance ISO UniProtKB:Q07917 2290270 (MGI:MGI:80763, PMID:1491694) MGI MGI:MGI:80763 , PMID:1491694 response to insecticide ISO UniProtKB:Q07917 2290270 (MGI:MGI:80706, PMID:8737662) MGI MGI:MGI:80706 , PMID:8737662 transcription, DNA-templated ISO UniProtKB:P43354 2290270 MGI GO_REF:0000096, MGI:MGI:4834177 transcription, DNA-templated IDA 2290270 (MGI:MGI:3830409, PMID:19144721) UniProtKB MGI:MGI:3830409 , PMID:19144721 Cellular Component cytoplasm ISO RGD:3202 2290270 RGD GO_REF:0000096, MGI:MGI:4417868 nuclear speck ISO UniProtKB:P43354 2290270 MGI GO_REF:0000096, MGI:MGI:4834177 nucleus ISO UniProtKB:P43354 2290270 MGI GO_REF:0000096, MGI:MGI:4834177 nucleus IBA MGI:MGI:1352454 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 nucleus IDA 2290270 (MGI:MGI:2156967 more ... MGI MGI:MGI:2156967 more ... nucleus ISO RGD:3202 2290270 RGD GO_REF:0000096, MGI:MGI:4417868 transcription factor complex IBA MGI:MGI:1352454 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 Molecular Function DNA binding IDA 2290270 (MGI:MGI:3029599, PMID:14671317) MGI MGI:MGI:3029599 , PMID:14671317 DNA-binding transcription activator activity, RNA polymerase II-specific IDA 2290270 (MGI:MGI:5572894 more ... UniProt MGI:MGI:5572894 more ... DNA-binding transcription activator activity, RNA polymerase II-specific ISO RGD:3202 2290270 MGI GO_REF:0000096, MGI:MGI:4417868 DNA-binding transcription activator activity, RNA polymerase II-specific IMP 2290270 (MGI:MGI:5572894, PMID:12122012) NTNU_SB MGI:MGI:5572894 , PMID:12122012 DNA-binding transcription factor activity IEA InterPro:IPR001628 2290270 UniProtKB GO_REF:0000002, MGI:MGI:2152098 glucocorticoid receptor binding IPI UniProtKB:P04150 2290270 (MGI:MGI:5644026, PMID:15591535) UniProtKB MGI:MGI:5644026 , PMID:15591535 glucocorticoid receptor binding IBA MGI:MGI:1352456 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 metal ion binding IEA UniProtKB-KW:KW-0479 2290270 UniProtKB GO_REF:0000004, MGI:MGI:1354194 nuclear receptor activity TAS 2290270 (MGI:MGI:87015, PMID:9092472) MGI MGI:MGI:87015 , PMID:9092472 protein binding IPI UniProtKB:P63017 2290270 (MGI:MGI:3798741, PMID:18346207) MGI MGI:MGI:3798741 , PMID:18346207 protein binding IPI UniProtKB:P12813 2290270 (MGI:MGI:5645213, PMID:10523643) MGI MGI:MGI:5645213 , PMID:10523643 protein binding IPI UniProtKB:O09106 more ... 2290270 (MGI:MGI:3830409, PMID:19144721) UniProtKB MGI:MGI:3830409 , PMID:19144721 protein binding IPI UniProtKB:P22829 2290270 (MGI:MGI:5645213, PMID:10523643) UniProtKB MGI:MGI:5645213 , PMID:10523643 protein binding IPI UniProtKB:O54943 2290270 (MGI:MGI:4429726, PMID:20159955) UniProtKB MGI:MGI:4429726 , PMID:20159955 protein binding IPI UniProtKB:Q62318 2290270 (MGI:MGI:5644023, PMID:19321449) UniProtKB MGI:MGI:5644023 , PMID:19321449 protein binding IPI UniProtKB:Q04207 , UniProtKB:Q8CFE3 2290270 (MGI:MGI:3850810, PMID:19345186) IntAct MGI:MGI:3850810 , PMID:19345186 protein binding IPI UniProtKB:Q8BPQ7 2290270 (MGI:MGI:3817825, PMID:18784308) MGI MGI:MGI:3817825 , PMID:18784308 protein binding IPI UniProtKB:P28700 2290270 (MGI:MGI:3817825, PMID:18784308) MGI MGI:MGI:3817825 , PMID:18784308 protein heterodimerization activity IPI UniProtKB:O75798 2290270 (MGI:MGI:84485, PMID:8961274) MGI MGI:MGI:84485 , PMID:8961274 protein heterodimerization activity IDA 2290270 (MGI:MGI:5645213, PMID:10523643) UniProtKB MGI:MGI:5645213 , PMID:10523643 RNA polymerase II cis-regulatory region sequence-specific DNA binding ISO RGD:3202 2290270 RGD GO_REF:0000096, MGI:MGI:4417868 RNA polymerase II cis-regulatory region sequence-specific DNA binding IBA MGI:MGI:1352456 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 RNA polymerase II cis-regulatory region sequence-specific DNA binding IDA 2290270 (MGI:MGI:3850580, PMID:19515692) MGI MGI:MGI:3850580 , PMID:19515692 RNA polymerase II regulatory region sequence-specific DNA binding IMP 2290270 (MGI:MGI:5572894, PMID:12122012) NTNU_SB MGI:MGI:5572894 , PMID:12122012 RNA polymerase II regulatory region sequence-specific DNA binding IBA FB:FBgn0014859 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 sequence-specific DNA binding ISO UniProtKB:Q07917 2290270 (MGI:MGI:80706, PMID:8737662) MGI MGI:MGI:80706 , PMID:8737662 sequence-specific DNA binding IBA MGI:MGI:1352454 more ... 2290270 (PMID:21873635) GO_Central PMID:21873635 sequence-specific DNA binding IDA 2290270 (MGI:MGI:84485, PMID:8961274) MGI MGI:MGI:84485 , PMID:8961274 steroid hormone receptor activity IEA InterPro:IPR001723 2290270 UniProtKB GO_REF:0000002, MGI:MGI:2152098 zinc ion binding IEA InterPro:IPR001628 , InterPro:IPR013088 2290270 UniProtKB GO_REF:0000002, MGI:MGI:2152098
Gene-Chemical Interaction Annotations
